Published in Hum Genet on June 03, 2003
Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut (2005) 2.00
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut (2007) 1.29
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr (2008) 1.13
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07
Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol (2008) 0.96
Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol (2007) 0.90
Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol (2014) 0.89
Molecular mechanisms of cholestasis. Wien Med Wochenschr (2006) 0.88
Fibrosis in autoimmune and cholestatic liver disease. Best Pract Res Clin Gastroenterol (2011) 0.87
The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther (2011) 0.84
Gene-gene and gene-environment interactions in ulcerative colitis. Hum Genet (2013) 0.79
CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol (2012) 0.77
Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol (2016) 0.75
Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep (2013) 0.75
A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics (1959) 12.04
Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med (1995) 6.56
Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med (1998) 5.79
The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr (1998) 5.08
The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med (1990) 4.70
Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science (1994) 3.97
Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med (1998) 3.91
Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med (1981) 3.85
Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med (1995) 3.55
Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet (1993) 3.22
The spectrum of cystic fibrosis mutations. Trends Genet (1992) 2.88
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest (1998) 2.68
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med (1994) 2.25
Genotype and phenotype in cystic fibrosis. Respiration (2000) 2.18
The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol (1995) 2.12
Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med (1999) 2.08
Primary sclerosing cholangitis. N Engl J Med (1995) 1.94
Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology (1993) 1.79
Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology (1991) 1.73
Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA (2000) 1.62
Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. Pediatrics (1996) 1.27
Liver and biliary problems in cystic fibrosis. Semin Liver Dis (1998) 1.06
CFTR mutation detection by multiplex heteroduplex (mHET) analysis on MDE gel. Methods Mol Med (2002) 0.98
Characterization of more than 85% of cystic fibrosis alleles in the Greek population, including five novel mutations. Hum Genet (1997) 0.92
Autonomic and airway reactivity in obligate heterozygotes for cystic fibrosis. Am Rev Respir Dis (1984) 0.89
Hepatobiliary disease in cystic fibrosis. Semin Liver Dis (1994) 0.87
Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. J Pediatr (2000) 0.87
Primary sclerosing cholangitis: a progressive disease? Semin Liver Dis (1991) 0.86
Three novel sequence variations in the 5' upstream region of the cystic fibrosis transmembrane conductance regulator (CFTR) gene: two polymorphisms and one putative molecular defect. Hum Genet (1995) 0.86
Biliary complications of cystic fibrosis. Gut (1992) 0.84
Characterization of mutations located in exon 18 of the CFTR gene. FEBS Lett (1998) 0.84
Congenital bilateral absence of the vas deferens (CBAVD) and cystic fibrosis transmembrane regulator (CFTR): correlation between genotype and phenotype. Hum Genet (1996) 0.82
Pancreatitis and mutations of the cystic fibrosis gene. N Engl J Med (1998) 0.81
Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol (1999) 0.81
Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology (1995) 0.78
Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol (2002) 0.78
Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. Dig Dis Sci (1996) 0.76
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Cystic fibrosis. Lancet (2009) 5.40
Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr (2008) 5.19
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet (2002) 4.62
Chylous ascites. Am J Gastroenterol (2002) 4.36
Genome-wide detection of segmental duplications and potential assembly errors in the human genome sequence. Genome Biol (2003) 4.32
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med (2004) 4.09
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol (2011) 3.53
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A (2010) 3.37
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst (2008) 3.16
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol (2008) 3.14
Human chromosome 7: DNA sequence and biology. Science (2003) 3.02
Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet (2011) 3.02
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet (2013) 2.91
A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain (2006) 2.91
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
Transcranial direct current stimulation of the unaffected hemisphere in stroke patients. Neuroreport (2005) 2.75
A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum (2006) 2.74
Confocal light absorption and scattering spectroscopic microscopy monitors organelles in live cells with no exogenous labels. Proc Natl Acad Sci U S A (2007) 2.56
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol (2007) 2.44
Chromosomal regions containing high-density and ambiguously mapped putative single nucleotide polymorphisms (SNPs) correlate with segmental duplications in the human genome. Hum Mol Genet (2002) 2.34
Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med (2006) 2.34
Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med (2009) 2.23
A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. Fertil Steril (2009) 2.08
Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome). Nat Genet (2005) 2.04
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
A sham-controlled trial of a 5-day course of repetitive transcranial magnetic stimulation of the unaffected hemisphere in stroke patients. Stroke (2006) 1.91
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol (2009) 1.91
Genetic modifiers of liver disease in cystic fibrosis. JAMA (2009) 1.88
Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr (2005) 1.87
Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology (2008) 1.87
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology (2002) 1.80
What is cystic fibrosis? N Engl J Med (2002) 1.76
PhenCode: connecting ENCODE data with mutations and phenotype. Hum Mutat (2007) 1.75
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol (2009) 1.68
Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in Xenopus oocytes. J Physiol (2003) 1.59
Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest (2008) 1.57
Pain in chronic pancreatitis: a salutogenic mechanism or a maladaptive brain response? Pancreatology (2007) 1.52
Glucose intolerance in children with cystic fibrosis. J Pediatr (2003) 1.51
Structural and mutational analysis of the SBDS protein family. Insight into the leukemia-associated Shwachman-Diamond Syndrome. J Biol Chem (2005) 1.51
Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol (2006) 1.48
Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J Pediatr (2007) 1.48
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Failure of conventional strategies to improve nutritional status in malnourished adolescents and adults with cystic fibrosis. J Pediatr (2005) 1.47
Clinical effects and brain metabolic correlates in non-invasive cortical neuromodulation for visceral pain. Eur J Pain (2010) 1.47
Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol (2004) 1.46
Airway inflammation and infection in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med (2003) 1.44
A systematic analysis of intronic sequences downstream of 5' splice sites reveals a widespread role for U-rich motifs and TIA1/TIAL1 proteins in alternative splicing regulation. Genome Res (2008) 1.44
Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med (2006) 1.44
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol (2008) 1.43
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol (2015) 1.43
A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy. Epilepsia (2006) 1.43
Definitions of pediatric pancreatitis and survey of present clinical practices. J Pediatr Gastroenterol Nutr (2012) 1.43
Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology (2007) 1.42
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int (2011) 1.41
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol (2011) 1.36
A novel missense mutation in the galactosyltransferase-I (B4GALT7) gene in a family exhibiting facioskeletal anomalies and Ehlers-Danlos syndrome resembling the progeroid type. Am J Med Genet A (2004) 1.34
Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology (2010) 1.33
Factors associated with enrollment in cancer genetics research. Cancer Epidemiol Biomarkers Prev (2006) 1.31
Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut (2007) 1.29
Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol (2008) 1.29